Insider Transactions in Q2 2025 at Esperion Therapeutics, Inc. (ESPR)
Insider Transaction List (Q2 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 17
2025
|
Benjamin Looker General Counsel |
SELL
Open market or private sale
|
Direct |
6,422
-1.58%
|
$6,422
$1.15 P/Share
|
|
Jun 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,229
-1.5%
|
$7,229
$1.15 P/Share
|
|
Jun 17
2025
|
Sheldon L. Koenig President and CEO |
SELL
Open market or private sale
|
Direct |
30,474
-1.94%
|
$30,474
$1.11 P/Share
|
|
May 29
2025
|
Seth H. Z. Fischer Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+35.05%
|
-
|
|
May 29
2025
|
J Martin Carroll Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+25.26%
|
-
|
|
May 29
2025
|
Jay Shepard Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+28.06%
|
-
|
|
May 29
2025
|
Stephen Rocamboli Director |
BUY
Grant, award, or other acquisition
|
Direct |
33,000
+32.27%
|
-
|
|
May 29
2025
|
Robert E. Hoffman Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,280
+50.0%
|
-
|
|
Apr 17
2025
|
Benjamin Halladay Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
8
-0.0%
|
$0
$0.96 P/Share
|
|
Apr 17
2025
|
Eric Warren Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
108
-0.03%
|
$0
$0.98 P/Share
|